CureMetrix vs HeartFlow

A cardiology or CT service that reads coronary CT angiograms is the HeartFlow buyer. FFRct Analysis gives CT-derived fractional flow reserve, first authorized by De Novo in November 2014 with later versions cleared by 510(k). Plaque Analysis quantifies and characterizes plaque (510(k), October 2022), and Roadmap Analysis supports consistent CCTA reads. Processing runs in the vendor's cloud. The FY2025 10-K describes revenue as pay-per-use, and no list price is published. CureMetrix is the call for a breast imaging practice that screens with mammography and wants calcification quantification, and the vendor says cmAngio returns results in minutes. A coronary CT service should skip CureMetrix, which reads mammograms. A breast practice should skip HeartFlow, which starts from a coronary CT angiogram. The answer follows the scan the department already reads: coronary CT points to HeartFlow, screening mammograms to CureMetrix.